Home Cart Sign in  
Chemical Structure| 1034688-30-6 Chemical Structure| 1034688-30-6

Structure of GSK2018682
CAS No.: 1034688-30-6

Chemical Structure| 1034688-30-6

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

GSK-2018682 is a sphingosine 1 phosphate receptor (S1PR)-1 agonist potentially for the treatment of multiple sclerosis. GSK-2018682 induced acute, transient and non-symptomatic decreases in heart rate and blood pressure.

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of GSK2018682

CAS No. :1034688-30-6
Formula : C22H21ClN4O4
M.W : 440.88
SMILES Code : O=C(O)CCCN1C=CC2=C1C=CC=C2C3=NOC(C4=CC(Cl)=C(OC(C)C)N=C4)=N3
MDL No. :MFCD18633078
InChI Key :NFIGDBFIDKDNIG-UHFFFAOYSA-N
Pubchem ID :24988201

Safety of GSK2018682

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302-H315-H319-H335
Precautionary Statements:P261-P280-P301+P312-P302+P352-P305+P351+P338

Related Pathways of GSK2018682

GPCR

Isoform Comparison

Biological Activity

Clinical Trial:

NCT Number Conditions Phases Recruitment Completion Date Locations
NCT01431937 Multiple Sclerosis, Relapsing-... More >>Remitting Less << Phase 1 Completed - Australia, New South Wales ... More >> GSK Investigational Site Randwick, New South Wales, Australia, 2031 Australia, South Australia GSK Investigational Site Adelaide, South Australia, Australia, 5000 Australia, Western Australia GSK Investigational Site Nedlands, Western Australia, Australia, 6009 Less <<
NCT01387217 Multiple Sclerosis Phase 1 Completed - Australia, New South Wales ... More >> GSK Investigational Site Randwick, New South Wales, Australia, 2031 Australia, South Australia GSK Investigational Site Adelaide, South Australia, Australia, 5000 Less <<
NCT01466322 Multiple Sclerosis, Relapsing-... More >>Remitting Less << Phase 1 Completed - Australia, Queensland ... More >> GSK Investigational Site Herston, Queensland, Australia, 4006 Less <<

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.27mL

0.45mL

0.23mL

11.34mL

2.27mL

1.13mL

22.68mL

4.54mL

2.27mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2
 

Historical Records

Categories